Eu­ro­pean reg­u­la­tor says ev­i­dence shows no thy­roid can­cer link to GLP-1s

Cur­rent ev­i­dence doesn’t sup­port a link be­tween GLP-1 re­cep­tor ag­o­nists and thy­roid can­cer, Eu­rope’s drug reg­u­la­tor an­nounced Fri­day fol­low­ing safe­ty con­cerns that have been raised for the pop­u­lar weight loss and di­a­betes drugs.

The Eu­ro­pean Med­i­cines Agency flagged a thy­roid can­cer safe­ty sig­nal ear­li­er this year over a 2022 study sug­gest­ing a po­ten­tial in­creased risk in pa­tients with type 2 di­a­betes. Af­ter re­view­ing da­ta from pub­li­ca­tions, ob­ser­va­tion­al stud­ies and drug­mak­ers (in­clud­ing clin­i­cal and post-mar­ket­ing da­ta), the EMA’s safe­ty com­mit­tee has de­ter­mined that “no up­dates to the prod­uct in­for­ma­tion are war­rant­ed based on the avail­able da­ta.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.